Similarities and distinctions in the mode of action of different classes of antioestrogens

Endocrine-Related Cancer

Volumn 7, Issue 1, 2000, Pages 17-28

  Wakeling, A E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ACOLBIFENE; ANTIESTROGEN; DROLOXIFENE; EM 562; ESTROGEN RECEPTOR BETA; ETHAMOXYTRIPHETOL; FULVESTRANT; IDOXIFENE; LASOFOXIFENE; LY 357489; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NAFOXIDINE; RALOXIFENE; SCH 57078; TAMOXIFEN; TOREMIFENE; TRIOXIFENE; UNCLASSIFIED DRUG; ZINDOXIFENE; ZK 119010; ZM 189154;

BREAST CARCINOMA; CANCER HORMONE THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034023827     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070017     Document Type: Review

References (148)

1. Albert JL, Sundstrom SA & Lyttle CR 1990 Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Research 50 3306-3310.
2. von Angerer E, Knebel N, Kager M & Ganss B 1990 1-Aminoalkyl-2-phenylindoles as novel pure estrogen antagonists. Journal of Medicinal Chemistry 33 2635-2640.
3. Aronica SM & Katzenellenbogen BS 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7 743-752.
4. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J & Jaffe RB 1998 Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. Journal of Clinical Endocrinology and Metabolism 83 6-13.
5. Beato M 1989 Gene regulation by steroid hormones. Cell 56 335-344.
6. Berry M, Metzger D & Chambon P 1990 Role of the two activating domains of the oestrogen receptor in cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal 9 2811-2818.
7. Black LJ & Good RL 1980 Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sciences 26 1453-1458.
8. Blin C, L'Horset F, Leclerc T, Lambert M, Colnot S, Thomasset M & Perret C 1995 Contrasting effects of tamoxifen and ICI 182780 on estrogen-induced calbindin-D 9k gene expression in the uterus and in primary culture of myometrial cells. Journal of Steroid Biochemistry 55 1-7.
9. Borras M, Laios I, El Khissiin A, Seo H-S, Lempereur F, Legros N & Leclercq G 1996 Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 57 203-213.
10. Bowler J, Lilley TJ, Pittam JD & Wakeling AE 1989 Novel steroidal pure antiestrogens. Steroids 54 71-99.
11. Bruning PF 1992 Droloxifene, a new anti-oestrogen in postmenopausal breast cancer: preliminary results of a double-blind dose-finding Phase II trial. European Journal of Cancer 28A 1404-1407.
12. Bryant H & Dere WH 1998 Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proceedings of the Society for Experimental Biology and Medicine 217 45-52.
13. Bucourt R, Vignau M, Torelli V, Richard-Foy H, Geynet C, Secco-Millet C, Redeuilh G & Baulieu EE 1978 New biospecific adsorbents for the purification of estradiol receptor. Journal of Biological Chemistry 253 8221-8228.
14. Buzdar AU, Marcus C, Holmes F, Hug V & Hortobagyi G 1988 Phase II evaluation of Ly 156758 in metastatic breast cancer. Oncology 45 344-345.
15. Bzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson J-A & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
16. Chen D, Pace PE, Coombes RC & Ali S 1999 Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Molecular and Cellular Biology 19 1002-1015.
17. Clarkson TB & Anthony MS 1997 Effects on the cardiovascular system: basic aspects. In Estrogens and Antiestrogens: Basic and Clinical Aspects, pp 89-118. Eds R Lindsay, DW Dempster & VC Jordan. Philadelphia: Lippincott-Raven.
18. Clemens JA, Bennett DR, Black LJ & Jones CD 1983 Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sciences 32 2869-2875.
19. Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R & Jarman M 1995 Idoxifene: report of a Phase I study in patients with metastatic breast cancer. Cancer Research 55 1070-1074.
20. Coopman P, Garcia M, Brunner N, Derocq D, Clarke R & Rochefort H 1994 Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen resistant human breast cancer cells. International Journal of Cancer 56 295-300.
21. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelson T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A & Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Journal of the American Medical Association 281 2189-2197.
22. Dauvois S, Danielian PS, White R & Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences of the USA 89 4037-1041.
23. Dauvois S, White R & Parker MG 1993 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106 1377-1388.
24. Day BW, Magarian RA, Jain PT, Pento JT, Mousissian GK & Meyer KL 1991 Synthesis and biological evaluation of a series of 1,1-dichloro-2,2,3-triarylcyclopropanes as pure antiestrogens. Journal of Medicinal Chemistry 34 842-851.
25. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blarney RW, Bundred N, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F & Wakeling AE 1995 Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research 54 408-414.
26. Delmas PD, Bjamason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M & Christianson C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 337 1641-1647.
27. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu E-E & Catelli M-G 1998 Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Molecular Endocrinology 12 842-854.
28. Dukes M, Chester R, Yarwood L & Wakeling AE 1994 Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. Journal of Endocrinology 141 335-341.
29. Duncan GW, Lyster SC, Clark JJ & Lednicer D 1963 Antifertility activities of two diphenyl-dihydronaphthalene derivatives. Proceedings of the Society for Experimental Biology and Medicine 112 439-142.
30. El-Tanani MK & Green CD 1997 Two independent mechanisms for ligand-independent activation of the estrogen receptor. Molecular Endocrinology 11 928-937.
31. Farhat MY, Lavigne MC & Ramwell PW 1996 The vascular protective effects of estrogen. FASEB Journal 10 615-624.
32. Fawell SE, White R, Hoare S, Sydenham M, Page M & Parker MG 1990 Inhibition of estrogen-receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences of the USA 87 6883-6887.
33. Fisher B, Costantino JP, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic NV, Dimitrov NV, Margolese RG, Kardinal CG et al. Study Group 1998 Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1. Journal of the National Cancer Institute 90 1371-1388.
34. Fornander T, Rutqvist LE, Wilking N, Carlstrom K & von Schoultz B 1993 Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. European Journal of Cancer 29A 497-500.
35. Furr BJA & Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics 25 127-205.
36. Galman MS, Sundstrom SA & Lyttle CR 1990 Antagonism of estrogen-and antiestrogen-induced uterine complement component C3 expression by ICI 164,384. Journal of Steroid Biochemistry 36 281-286.
37. Gaub M-P, Bellard M, Scheuer I, Chambon P & Sassone-Corsi P 1990 Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex. Cell 63 1267-1276.
38. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Lablanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C & Labrie F 1997 (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2[4-[2-(1-piperidinyl)-ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM 800): a highly potent, specific, and orally active nonsteroidal antiestrogen. Journal of Medicinal Chemistry 40 2117-2122.
39. Gibson MK, Nemmers LA, Beckman WC Jr, Davis VL, Curtis SW & Korach KS 1991 The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129 2000-2010.
40. Gottardis MM & Jordan VC 1987 Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Research 47 4020-4024.
41. Gottardis MM, Robinson SP, Satyaswaroop PG & Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 48 812-815.
42. Gottardis MM, Jiang S-Y, Jeng M-H & Jordan VC 1989 Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 49 4090-4093.
43. Gottardis MM, Ricchio ME, Satyaswaroop PG & Jordan VC 1990 Effect of steroidal and nonsteroidal antiestrogens on the growth of tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Research 50 3189-3192.
44. Grese TA, Sluka JP, Bryant HU, Cole HW, Kim JR, Magee DE, Rowley ER & Sato M 1996 Benzpyran selective estrogen receptor modulators (SERMS): pharmacological effects and structural correlation with raloxifene. Bioorganic and Medicinal Chemistry Letters 6 903-908.
45. Grese TA, Pennington LD, Sluka JP, Adrian MD, Cole HW, Fuson TR, Magee DE, Phillips L, Rowley ER, Shetler PK, Short LL, Venugopalan M, Yang NN, Sato M, Glasebrook AL & Bryant HU 1998 Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. Journal of Medicinal Chemistry 41 1272-1283.
46. Harper MJK & Walpole AL 1967a A new derivative of triphenylethylene: effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 13 101-119.
47. Harper MJK & Walpole AL 1967b Mode of action of ICI 46,474 in preventing implantation in rats. Journal of Endocrinology 37 83-92.
48. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS & Tung L 1996 Nuclear receptor coactivators and corepressors. Molecular Endocrinology 10 1167-1177.
49. Howell A, DeFriend D, Robertson J, Blarney R & Walton P 1995 Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 29-30.
50. Howell A, DeFriend DJ, Robertson JFR, Blarney RW, Anderson L, Anderson E, Sutcliffe FA & Walton P 1996 Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. British Journal of Cancer 74 300-308.
51. Htun H, Holth LT, Walker D, Davie JR & Hager GL 1999 Direct visualization of the human estrogen receptor a reveals a role for ligand in the nuclear distribution of the receptor. Molecular Biology of the Cell 10 471-486.
52. Huynh HT & Pollack M 1993 Insulin-like growth faclor-I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Research 53 5585-5588.
53. Huynh H & Pollack M 1994 Uterotropic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein-3 gene expression. Cancer Research 54 3115-3119.
54. Huynh H, Yang X-F & Pollak M 1996 A role for insulin-like growth factor binding protein-5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth and Differentiation 7 1501-1506.
55. Hyder SM, Chieppetta C, Murthy L & Stancel GM 1997 Selective inhibition of estrogen-regulaled gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Research 57 2547-2549.
56. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS & McLachlan JA 1993 Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Molecular Endocrinology 7 992-998.
57. Jamil A, Croxtall JD & White JO 1991 The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). Journal of Molecular Endocrinology 6 215-221.
58. Jones CD, Suarez T, Massey EH, Black LJ & Tinsley J 1979 Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-(1-pyrolidinyl) ethoxyphenyl methanone, methanesulphonic acid salt. Journal of Medicinal Chemistry 22 962-966.
59. Jordan VC & Murphy CS 1990 Endocrine pharmacology of anti-estrogens as antitumor agents. Endocrine Reviews 11 578-610.
60. Kangas L 1990 Review of the pharmacological properties of toremiphene. Journal of Steroid Biochemistry 36 191-195.
61. Kassem M, Harris SA, Spelsberg TC & Riggs BL 1996 Estrogen inhibits interleukin-6 production in a human osteoblastic cell line with high levels of estrogen receptors. Journal of Bone and Mineral Research 11 193-199.
62. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D & Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
63. Katzenellenbogen JA, O'Malley BW & Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promotor-specific action of these hormones. Molecular Endocrinology 10 119-131.
64. Kauffman RF & Bryant HU 1995 Selective estrogen receptor modulators. Drug News and Perspectives 8 531-539.
65. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WSS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P & Thompson DD 1998 Effects of CP-336,156, a new nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139 2068-2076.
66. Kimble RB, Bain SD & Pacifici R 1997 The functional block of TNF but not IL-6 prevents bone loss in ovariectomized mice. Journal of Bone and Mineral Research 12 935-941.
67. Korach K 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266 1524-1527.
68. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson J-Å & Smithies O 1998 Generation and reproductive phenotypes in mice lacking estrogen receptor β. Proceedings of the National Academy of Sciences of the USA 95 15677-15682.
69. Kuiper GGJM & Gustafsson J-Å 1997 The novel estrogen receptor-β subtype: potential role in the cell-and promotor-specific actions of estrogens and anti-estrogens. FEBS Letters 410 87-90.
70. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson BS & Gustafsson J-Å 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the USA 93 5925-5930.
71. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S & Gustafsson J-Å 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 863-870.
72. Kuiper GGJM, Shughrue PJ, Merchenthaler I & Gustafsson J-Å 1998 The estrogen receptor β subtype: a novel mediator of estrogen action in neuroendocrine systems. Frontiers in Neuroendocrinology 19 253-286.
73. Kumar V, Green S, Stack G, Berry M, J in J-R & Chambon P 1987 Functional domains of the human estrogen receptor. Cell 51 941-951.
74. Kurebayashi S, Miyashita Y, Hirose T, Kasayama S, Akira S & Kishimoto T 1997 Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology 60 11-17.
75. Labrie, F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, Merand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L & Veilleux R 1999 EM-652 (SCH 57068), a third generation SERM acting as a pure antiestrogen in the mammary gland and endometrium. Journal of Steroid Biochemistry and Molecular Biology 69 51-84.
76. Lerner LJ, Holthaus JF & Thompson 1958 A nonsteroidal estrogen antagonist (1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 63 295-318.
77. Levenson AS & Jordan VC 1998 The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (Aspartate) in the estrogen receptor. Cancer Research 58 1872-1875.
78. Levesque C, Merand Y, Dufour JM, Labrie C & Labrie F 1991 Synthesis and biological activity of new halo-steroidal antiestrogens. Journal of Medicinal Chemistry 34 1624-1630.
79. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS & Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proceedings of the National Academy of Sciences of the USA 90 11162-11166.
80. Lundeen SG, Carver JM, McKean M-L & Winneker RC 1997 Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology 138 1552-1558.
81. Luo S, Martel C, Sourla A, Gauthier S, Merand Y, Belanger A, Labrie C & Labrie F 1997 Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. International Journal of Cancer 73 381-391.
82. Luo S, Sourla A, Labrie C, Gauthier S, Merand Y, Belanger A & Labrie F 1998 Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology 139 2645-2656.
83. R-1. Cancer Research 54 1587-1595.
84. McDonnell DP & Norris JD 1997 Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen on the bone. Osteoporosis International Supplement 1 S29-S34.
85. McDonnell DP, Clemm DL, Hermann T, Goldman ME & Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocrinology 9 659-669.
86. Macgregor JI & Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacological Reviews 50 151-196.
87. Macgregor JI & Jordan VC 1999 Classification of the antiestrogen EM-800 using a novel assay system. Proceedings of the American Association of Cancer Research 40 639 (Abstract 4212).
88. McInerney EM, Weis KE, Sun J, Mosselman S & Katzenellenbogen BS 1998 Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras. Endocrinology 139 4513-4522.
89. Mäkelä S, Savolainen H, Aavik E, Myllärniemei M, Strauss L, Taskinen E, Gustafsson J-Å & Häyry P 1999 Differentiation between vasculoprotective and uterotropic effects of ligands with differing binding affinities to estrogen receptors α and β. Proceedings of the National Academy of Sciences of the USA 96 7077-7082.
90. Malayer JR, Cheng J & Woods VM 1999 Estrogen responses in bovine fetal uterine cells involve pathways directed by both estrogen response element and activator protein-1. Biology of Reproduction 60 1204-1210.
91. Manning DL & Nicholson RI 1993 Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins. European Journal of Cancer 29 759-762.
92. May FEB, Johnson MD, Wiseman LR, Wakeling AE, Kastner P & Westley BR 1989 Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. Journal of Steroid Biochemistry 33 1035-1041.
93. Mitlak BH & Cohen FJ 1997 In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Hormone Research 48 155-163.
94. Montano MM & Katzenellenbogen BS 1997 The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proceedings of the National Academy of Sciences of the USA 94 2581-2586.
95. Mosselman S, Polman J & Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392 49-53.
96. Müller V, Jensen EV & Knabbe C 1998 Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Research 58 263-267.
97. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagatto U & Stalla G 1994 The unliganded estrogen receptor (ER) transduces growth factor signals. Journal of Steroid Biochemistry and Molecular Biology 48 481-186.
98. Nicholson RI, Gotting KE, Gee J & Walker KJ 1988 Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. Journal of Steroid Biochemistry 30 95-103.
99. Nicholson RI, Gee JMW, Manning DL, Wakeling AE, Montano MM & Katzenellenbogen BS 1995 Responses to pure anti-oestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Annals of the New York Academy of Sciences 761 148-162.
100. Nique F, Van de Velde P, Bremaud J, Hardy M, Philibert D & Teutsch G 1994 11β-Amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. Journal of Steroid Biochemistry and Molecular Biology 50 21-29.
101. Nishino Y, Schneider MR, Michna H & von Angerer E 1991 Pharmacological characterisation of novel oestrogen antagonist, ZK 119010, in rats and mice. Journal of Endocrinology 130 409-414.
102. Norris JD, Fan D, Kemer SA & McDonnell DP 1997 Identification of a third autonomous activation domain within the human estrogen receptor. Molecular Endocrinology 11 747-754.
103. Norris JD, Paige LA, Christensen DJ, Chang C-Y, Huacani MR, Fan D, Hamilton PT, Fowlkes DM & McDonnell P 1999 Science 285 744-746.
104. Ordog T, Goldsmith JR, Chen M-D, Connaughton MA, Hotchkiss J & Knobil E 1998 On the mechanism of the positive feedback action of estradiol on luteinizing hormone secretion in the rhesus monkey. Journal of Clinical Endocrinology and Metabolism 83 4047-4053.
105. O'Regan RM, Cisneros A, England GM, MacGreogor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R & Jordan VC 1998 Effects of the antiestrogens tamoxifen, toremiphene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute 90 1552-1558.
106. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG & Wakeling AE 1994 The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumour growth. Cancer Chemotherapy and Pharmacology 34 89-95.
107. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
108. Pace P, Taylor J, Suntharalingam S, Coombes RC & Ali S 1997 Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor a. Journal of Biological Chemistry 272 25832-25838.
109. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERa and ERβ at AP1 sites. Science 277 1508-1510.
110. Paganini-Hill A 1997 Does estrogen replacement therapy protect against Alzheimer's disease? Osteoporosis International Supplement 1 S12-S17.
111. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C-Y, Ballas LM, Hamilton PT & McDonnell DP 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERβ. Proceedings of the National Academy of Sciences of the USA 96 3999-4004.
112. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR & Bryant HU 1997 Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. Journal of Medicinal Chemistry 40 1407-1416.
113. Pasqualini JR, Giambiagi N, Gelly C & Chetrite G 1990 Antiestrogen action in mammary cancer and in fetal cells. Journal of Steroid Biochemistry 37 343-348.
114. 2, a functional variant of estrogen receptor β expressed in normal rat tissues. Endocrinology 139 1082-1092.
115. Pettersson K, Grandien K, Kuiper GGJM & Gustafsson J-Å 1997 Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Molecular Endocrinology 11 1486-1496.
116. Pink JJ & Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Research 56 2321-2330.
117. Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC & Riggs BL 1998 Bone morphometric protein-6 production in human osteoblastic cell lines. Journal of Clinical Investigation 101 413-422.
118. Robinson JA, Riggs BL, Spelsberg TC & Oursler MJ 1996 Osteoclasts and transforming growth factor-β: estrogen-mediated isoform-specific regulation of production. Endocrinology 137 615-621.
119. Sharma AP, Saeed A, Durani S & Kapil RS 1990 Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. Journal of Medicinal Chemistry 33 3222-3229.
120. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1999 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
121. Shughrue PJ, Lane MV & Merchenthaler I 1997 Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study. Endocrinology 138 5476-5484.
122. Sibonga JD, Dobnig H, Harden RM & Turner RT 1998 Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139 3736-3742.
123. Smith CL, Conneely OM & O'Malley BW 1993 Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proceedings of the National Academy of Sciences of the USA 90 6120-6124.
124. Stein B & Yang MX 1995 Repression of the interleukin-6 promotor by estrogen receptor is mediated by NF-κB and C/ EBPβ. Molecular and Cellular Biology 15 4971-1979.
125. Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet J-C, von Angerer E & Coombes RC 1990 Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II clinical trials committee study. British Journal of Cancer 61 451-453.
126. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA & Katzenellenbogen BS 1999 Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 140 800-804.
127. Thomas EJ, Walton PL, Thomas NM & Dowsett M 1994 The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-ovarian axis and on endometrial proliferation in pre-menopausal women. Human Reproduction 9 1991-1996.
128. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E & Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 477-187.
129. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F & Giguere V 1997 Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Molecular Endocrinology 11 353-365.
130. Tremblay GB, Tremblay A, Labrie F & Giguere V 1998 Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Research 58 877-881.
131. Tremblay GB, Tremblay A, Labrie F & Giguere V 1999 Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex. Molecular and Cellular Biology 19 1919-1927.
132. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
133. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker M, Stein RB, Pike JW & McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promotor context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8 21-30.
134. Wade GN, Blaustein JD, Gray JM & Meredith JM 1993 ICI 182,780: a pure antiestrogen that affects behaviours and energy balance in rats without acting in the brain. American Journal of Physiology 43 R1392-R1398.
135. Wakeling AE 1993 The future of new pure antioestrogens in clinical breast cancer. Breast Cancer Research and Treatment 25 1-9.
136. Wakeling AE 1995 Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochemical Pharmacology 49 1545-1549.
137. Wakeling AE & Bowler J 1987 Steroidal pure antioestrogens. Journal of Endocrinology 112 R7-R10.
138. Wakeling AE, Newboult E & Peters SW 1989 Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. Journal of Molecular Endocrinology 2 225-234.
139. Wakeling AE, Dukes M & Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Research 51 3867-3873.
140. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS & Anderson PW 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Journal of the American Medical Association 279 1445-1451.
141. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A & Muramatsu M 1997 Agonistic effect of tamoxifen is dependent on cell type, ERE-promotor context, and estrogen receptor subtype: functional difference between estrogen receptors α and β. Biochemical and Biophysical Research Communications 236 140-145.
142. Webb P, Lopez N, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443-456.
143. White R & Parker MG 1998 Molecular mechanisms of steroid hormone action. Endocrine-Related Cancer 5 1-14.
144. Wickelgren I 1997 Estrogen stakes claim to cognition. Science 276 675-678.
145. Willson TM, Morris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC & McDonnell DP 1997 Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138 3901-3911.
146. Wiseman LR, Wakeling AE, May FEB & Westley BR 1989 Effects of the antioestrogen, ICI 164,84, on oestrogen induced RNAs in MCF-7 cells. Journal of Steroid Biochemistry 33 1-6.
147. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJS, Glasebrook AL & Termine JD 1996 Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 137 2075-2084.
148. Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE & Allegretto EA 1999 Estrogen receptor β activates the human retinoic acid receptor α-1 promotor in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Molecular Endocrinology 13 418-430.